Related Experiment Video
Updated: Jul 29, 2025
12:35
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
Published on: March 17, 2012
28.2K
Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical
Lakshmi Balaji1,2, Michelle A Farrar1,2,3, Arlene M D'Silva1,2,3
1Department of Neurology, Sydney Children's Hospital Network, Sydney, New South Wales, Australia.
Expert Review of Neurotherapeutics
|May 25, 2023
Summary
Disease modifying therapies have transformed spinal muscular atrophy (SMA) care from symptomatic treatment to proactive intervention. Early diagnosis and newborn screening are crucial for improved outcomes in SMA management.
Area of Science:
- Neurology
- Genetics
Background:
- Disease modifying therapies have revolutionized spinal muscular atrophy (SMA) management, shifting from symptomatic care to proactive and preventative strategies.
- The advent of SMN-augmenting therapies has enabled personalized medicine approaches for SMA patients.
Purpose of the Study:
- To evaluate the current therapeutic landscape for SMA.
- To discuss the evolution of SMA phenotypes and treatment algorithms.
- To highlight the importance of early diagnosis and newborn screening.
Main Methods:
- Review of contemporary SMA therapeutic landscape.
- Analysis of emerging phenotypes and treatment response factors.
- Appraisal of prognostic methods and classification frameworks.
Main Results:
- SMN-augmenting therapies have significantly improved health outcomes in SMA.
- New SMA phenotypes and disease trajectories are emerging due to proactive treatment.
- Early diagnosis and treatment through newborn screening yield substantial benefits.
Conclusions:
- Personalized medicine is advancing SMA care.
- Understanding emerging phenotypes and disease trajectories is critical.
- Continued research is essential to address unmet needs and refine future SMA treatment strategies.
Keywords:
RNA therapySpinal Muscular Atrophydisease modifying therapiesgene therapynewborn screeningphenotypesMore Related Videos
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
1.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
01:21Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K